Two Onc Docs

OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.

In this episode, Two Onc Docs review the current management of metastatic breast cancer, emphasizing treatment strategies across molecular subtypes.

Drs Armstrong and Tawagi discuss key aspects of soft tissue sarcoma management.

Drs Armstrong and Tawagi reviewed diagnostic, staging, and treatment principles in uterine cancer and recent advances in immunotherapy.

Drs Armstrong and Tawagi discussed key data from the phase 3 MATTERHORN trial, which were presented at the 2025 ASCO Annual Meeting.

Drs Armstrong and Tawagi discuss key efficacy, safety, and patient-reported outcomes from the phase 3 SERENA-6 study.

Drs Armstrong and Tawagi discuss the board review plans they followed in the months leading up to their hematology and oncology board exams.

Drs Armstrong and Tawagi discuss high-yield oncology and hematology topics to focus on when studying for the 2024 oncology board exams.

Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III melanoma.

OncLive On Air partners with Two Onc Docs to bring insights on primary data from the LAURA trial, which were presented at the 2024 ASCO Annual Meeting.